Omicron News and Research

RSS

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

A recent study investigated the disease severity of SARS-CoV-2 Omicron BA.2 infection among Hong Kong children.

28 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

Clinical determinants of post-COVID-19 thromboembolism

Researchers quantify the risk of acute VTE due to SARS-CoV-2 infection in ambulatory settings.

27 Mar 2022

U.S. traveler-based genomic surveillance provided early SARS-CoV-2 variant detection

Researchers discuss their efforts to detect SARS-CoV-2 and its variants in travelers entering the United States.

27 Mar 2022

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

Researchers investigated the impact of mutations in the SARS-CoV-2 variants of interest and variants of concern on the properties of the cluster of differentiation 8 T lymphocytes.

25 Mar 2022

A new strategy for identifying potent miniature antibodies against emerging SARS-CoV-2 variants

Researchers at Karolinska Institutet in Sweden have developed a novel strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants.

25 Mar 2022

SARS-CoV-2 virus may have lingering effects on peripheral nerves

Adding to a growing body of evidence that, for many, problems related to COVID-19 linger longer than the initial infection, researchers at Washington University School of Medicine in St. Louis have found that some people infected during the pandemic's early months experienced peripheral neuropathy - pain, tingling and numbness in the hands and feet - during and following their bouts with the virus.

25 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers evaluated the neutralizing antibody titers and anti-receptor-binding domain immunoglobulin G titers in sera of kidney transplant recipients who were vaccinated against COVID-19 and treated with 300 mg dosage of Evusheld™

25 Mar 2022

Algae found to inhibit SARS-CoV-2 infection in vitro

A new study demonstrated that dry algal powders inhibit SARS-CoV-2 in vitro.

25 Mar 2022

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Researchers evaluated clinical accuracy and analytical detection capabilities of the two US Food and Drug Administration-approved rapid antigen tests across SARS-CoV-2 variants.

25 Mar 2022

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

25 Mar 2022

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection incites adaptive cellular immune responses. In many SARS-CoV-2 studies, peripheral blood is analyzed to study the immune responses. Now, a new study under consideration at the Nature Portfolio Journal analyzes the peripheral blood, tonsils, and adenoids of children to understand local and systemic immune responses to SARS-CoV-2.

25 Mar 2022

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A research paper published in the New England Journal of Medicine has demonstrated how a third dose of Pfizer-BioNTech (BNT162b2) vaccine administered in a median period of 10.8 months after the second one bestowed 95.3% efficacy against coronavirus disease 2019 (COVID-19), in comparison with two doses of the same vaccine during a median follow-up of 2.5 months.

24 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Brain fog in post-COVID Canadians

A new study confirms that a history of COVID-19 is a risk factor for cognitive dysfunction in the young and middle-aged.

24 Mar 2022

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Researchers evaluated the effectiveness of a novel vaccine candidate UB-612 against 14 SARS-CoV-2 variants, including the latest variant of concern, Omicron.

24 Mar 2022

Omicron News and Research

Benefits of heterotypic vaccination against variants of SARS-CoV-2

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Clinical determinants of post-COVID-19 thromboembolism

U.S. traveler-based genomic surveillance provided early SARS-CoV-2 variant detection

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

A new strategy for identifying potent miniature antibodies against emerging SARS-CoV-2 variants

SARS-CoV-2 virus may have lingering effects on peripheral nerves

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Algae found to inhibit SARS-CoV-2 infection in vitro

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Adaptive immunity against SARS-CoV-2 is persistent and robust in COVID-convalescent children

Study shows third dose of Pfizer-BioNTech vaccine against COVID-19 is both safe and effective

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Brain fog in post-COVID Canadians

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News